SC
NGM

Steven Cohen’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Steven Cohen’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,116
Closed -$94.3K – 2921
2023
Q1 		$94.3K Buy
+23,116
New +$107K ﹤0.01% 1644
2022
Q4 		– Sell
-362,900
Closed -$4.75M – 1865
2022
Q3 		$4.75M Sell
362,900
-957,762
-73% -$14.5M 0.02% 742
2022
Q2 		$16.9M Sell
1,320,662
-1,890,209
-59% -$26.2M 0.07% 356
2022
Q1 		$49M Sell
3,210,871
-87,027
-3% -$1.36M 0.19% 149
2021
Q4 		$58.4M Buy
3,297,898
+1,854,904
+129% +$35.6M 0.23% 107
2021
Q3 		$30.3M Buy
1,442,994
+578,794
+67% +$12.7M 0.13% 209
2021
Q2 		$17M Sell
864,200
-1,310,800
-60% -$30.7M 0.08% 323
2021
Q1 		$63.2M Buy
2,175,000
+413,843
+23% +$11.6M 0.3% 76
2020
Q4 		$53.4M Buy
1,761,157
+149,307
+9% +$3.27M 0.26% 85
2020
Q3 		$25.6M Buy
1,611,850
+88,265
+6% +$1.61M 0.13% 215
2020
Q2 		$30.1M Buy
1,523,585
+527,290
+53% +$10.1M 0.2% 147
2020
Q1 		$12.3M Buy
+996,295
New +$16.3M 0.1% 283

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Steven Cohen's NGM Position: Q2 2023 in Review

Steven Cohen sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 23,116 shares — an estimated $94.3K sold.

Steven Cohen first reported a position in NGM in Q1 2020 and held it in 12 quarters. The position peaked at $63.2M in Q1 2021. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • Steven Cohen reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Steven Cohen sold 23,116 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $94.3K.
  • Steven Cohen first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Steven Cohen's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $63.2M in Q1 2021.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.